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Abstract
The tumor suppressor p53 principally functions as a gene-specific transcription factor. p53 triggers a variety of anti-
proliferative programs by activating or repressing the transcription of effector genes in response to genotoxic stress. To
date, much effort has been placed on understanding p53’s ability to affect transcription in the context of its DNA-binding
activity. How p53 regulates transcriptional output independent of DNA binding is less well understood. Here we provide
evidence that human p53 can physically interact with the large subunit of RNA polymerase II (Pol II) both in in vitro
interaction assays and in whole cell extracts, and that this interaction is mediated (at least in part) through p53’s core DNA-
binding domain and the Ser5-phosphorylated CTD of Pol II. Ectopic expression of p53, combined with mutations in
transcription elongation factors or exposure to drugs that inhibit Pol II elongation, elicit sickness or lethality in yeast cells.
These phenotypes are suppressed by oncogenic point mutations within p53’s core domain. The growth phenotypes raise
the possibility that p53 impairs Pol II elongation. Consistent with this, a p53-dependent increase in Pol II density is seen at
constitutively expressed genes without a concomitant increase in transcript accumulation. Additionally, p53-expressing
yeast strains exhibit reduced transcriptional processivity at an episomal reporter gene; this inhibitory activity is abolished by
a core domain point mutation. Our results suggest a novel mechanism by which p53 can regulate gene transcription, and a
new biological function for its core domain that is susceptible to inactivation by oncogenic point mutations.
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Introduction
p53 is a tumor suppressor that transcriptionally regulates
upwards of 2500 genes in response to genotoxic stress. In so
doing, it triggers a variety of anti-proliferative programs [1].
Through its sequence-specific binding, p53 can promote tran-
scription of genes involved in cell cycle arrest, apoptosis, and DNA
repair. Targeted differently, it can repress transcription of genes
involved in survival, G2/M transition, and metastasis [2,3]. p53
contains four principal functional domains: an N-terminal
transactivation domain, a core DNA binding domain, a tetra-
merization domain and a C-terminal regulatory domain [4]. At
the N-terminus, there are two highly acidic transactivation (TA)
domains, TA1 (amino acids 1–40) and TA2 (amino acids 40–83)
[5,6]. Each domain has distinct interacting partners and exhibits
independent transactivation activity [7]. Together they mediate
p53’s interaction with several general transcription factors (GTFs)
including TBP, TAF1, TFIIB and TFIIH to stimulate gene
transcription [8,9]. The tetramerization domain (amino acids 325–
356) mediates intermolecular formation of four p53 monomers to
form a tightly packed tetramer, which is biologically active and
efficiently binds to p53 response elements (PREs). The regulatory
domain (amino acids 363–393) exhibits extensive post-translation-
al modification [10] and has been implicated in regulating both
p53’s transactivation and DNA binding activities [11,12].
Because of p53’s critical role in tumor suppression, mutations
within the p53 gene are found in nearly half of all human cancers
[13]. 97% of these are missense mutations that map to the core
domain (amino acids 102–292), a region that plays a key role in
mediating p53’s tumor suppressive activity [14,15]. The core
domain not only exhibits sequence-specific DNA binding activity
within the nucleus, it also has a cytoplasmic role in which it
activates Bax, leading to permeabilization of the outer mitochon-
drial membrane and initiation of the apoptotic cascade [16].
The core domain is composed of a common immunoglobulin
scaffold with a DNA-binding surface formed by a loop–sheet–helix
(LSH) motif and two b-turn loops (L2 and L3) tethered by a single
zinc atom [17]. Six ‘‘hot spot’’ mutations map to the core domain
and these mutations are divided into two classes depending on their
effect on protein folding and DNA-binding ability [18]. Contact
mutations such as R248W (L3) and R273H (ß-sheet 10 [S10] in
LSH) abolish p53’s ability to bind specific DNA sequences and
activate expression of its target genes. Conformational mutations
occur in amino acids required for maintenance of p53 structure and
disrupt the structural stability of p53. Examples include R175H
(L2), G245D (L3), R249S (L3), and V143A (ß-sandwich) [14,19].
These mutations can reduce the binding activity of p53 to its DNA
sequence, specific peptides, and cellular and viral proteins [20,21].
Therefore, mutations in the core domain of p53 can affect cell fate
not only by regulating DNA binding activity, but also by interfering
with p53’s protein interactions.
Previous work has shown that p53’s interactions with GTFs
and co-activators are crucial to promote or inhibit target gene
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activator of transcription, less is known of the mechanisms by
which p53 represses transcription. Indeed, significant numbers of
genes are down-regulated in a p53-dependent manner. This
repression mechanism appears to be more diverse than p53-
mediated transcription activation [22]. Proposed mechanisms
include (i) inhibiting the assembly of the PIC and (ii) remodeling
chromatin structure by recruitment of histone deacetylases
(HDACs) and other enzymatic complexes [9]. Importantly, it
has been suggested that binding of p53 to its DNA sequence is not
necessary for its inhibitory activity, although the presence of a
functionally active core domain is required [9,23]. In addition,
several studies have raised the possibility that p53 is involved in
regulating transcription elongation as a consequence of the cross-
talk between events at the promoter and those regulating
elongation [24]. Indeed, p53 can interact with proteins that are
involved in elongation. An example of this is TFIIH [25], which
has been shown to be involved not only in initiation but also in
promoter escape [26]. The Pol II elongation factor ELL has also
been reported as a physical and functional interacting partner of
p53 [27]. Interestingly, this physical association leads to suppres-
sion of p21 transcription. Likewise, hPAF1C, an elongation factor,
directly interacts with p53 both in vitro and in vivo (cited in [28]).
In this study, we extend our earlier analysis suggesting that p53
can physically interact with Pol II, both in vivo and in vitro [29] . We
provide evidence that p53’s physical and functional interaction
with Pol II requires integrity of its core domain, and that
expression of p53 in the model eukaryote Saccharomyces cerevisiae
impairs Pol II elongation at both chromosomal and episomal
genes. Oncogenic mutations within the p53 core domain obviate
this effect. These and other results suggest a novel mechanism by
which p53 can regulate gene transcription in eukaryotic cells.
Results
p53 preferentially binds to peptides that mimic the
phosphorylated state of the Pol II CTD
Previous work from our laboratory has suggested that p53 may
regulate Pol II elongation through a novel mechanism that
involves its physical interaction with the Pol II large subunit, Rpb1
[29]. To explore this possibility further, we investigated whether
p53 can bind the phosphorylated C-terminal domain (CTD) of
Rpb1. We employed synthetic peptides mimicking the CTD,
which consists of heptad repeats of the evolutionarily conserved
sequence, YSPTSPS (26 repeats in yeast, 52 in human), and acts as
a platform for the binding of regulatory factors during transcrip-
tion [30]. As elongating RNA polymerase is characterized by
phosphorylation at Ser5 and/or Ser2 within the heptad repeat, we
tested p53 affinity for synthetic peptides bearing four perfect
heptad repeats that were unmodified or phosphorylated at one or
the other residue. Unphosphorylated, Ser5-phosphorylated or
Ser2-phosphorylated peptides biotinylated on their N-terminus
were incubated with recombinant human p53. Bound and
unbound fractions were subjected to immunoblot analysis, and
peptide-bound p53 was quantified as the ratio of bound p53 to
unbound p53. As shown in Figure 1 (panels A and B), human
p53 preferentially binds Ser5-phosphorylated CTD peptides
(P=0.058), and to a lesser degree Ser2- phosphorylated CTD
peptides (P=0.11). It shows no affinity for the unphosphorylated
peptide over beads alone. Taken together with observations that
p53 and Rpb1 co-purify from yeast whole cell extracts (WCEs) (see
below), these assays suggest that p53 can physically interact with
the Pol II large subunit through its phosphorylated CTD (see
Discussion).
The core domain of p53 is required for the p53-Rpb1
interaction
Physical association of p53 with the Pol II large subunit raises
the question of which domain of p53 is responsible for mediating
this interaction. It has been previously shown that the presence of
the core DNA-binding domain is required for p53-dependent
repression, although binding of p53 to PREs is unnecessary [9,23].
Based on this, we hypothesized that the core domain might
mediate p53’s interaction with Pol II, and performed a reciprocal
co-immunoprecipitation (co-IP) comparing full-length p53 (p53
+)
with core domain-deleted p53 (p53
coreD). Both p53
+ and p53
coreD
(Figure 2A) were expressed from integrated, GAL1-regulated
genes. Immunoblot analysis shows that p53
coreD is expressed at
levels similar to that of full-length p53 in cells grown in the
presence of 0.2% galactose/1.8% raffinose (Figure 2B). As
observed previously [29], Rpb1 co-immunoprecipitates with full-
Figure 1. p53 Binds to Peptides that Mimic the Phosphorylated Pol II CTD. Biotinylated CTD peptides bearing four heptad repeats (28-mers)
that were unphosphorylated (CTD), Ser5-phosphorylated (Ser5-P-CTD), or Ser2-phosphorylated (Ser2-P-CTD), were adsorbed to streptavidin-coated
magnetic beads. Recombinant HA-p53, bearing an HA tag on its N-terminus, was incubated with beads alone or beads bearing peptides. Bound
proteins (B) and those remaining in the supernatant (S) were subjected to SDS-PAGE and the presence of p53 was detected using the 1801 mAb. (B)
Graphical summary of peptide-bound p53 relative to unbound p53. Depicted are means 6 S.E.M. (N=4). A two-sample t-test (two-tailed, equal
variance) comparing p53 binding to the Ser5-phosphorylated CTD peptide vs. the unphosphorylated CTD peptide results in a P value of 0.058. A
corresponding analysis of p53 binding to the Ser2-phosphorylated CTD peptide results in a P value of 0.11.
doi:10.1371/journal.pone.0022183.g001
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antibody (mAb) DO-1 (Figure 2C, lane 2). In important contrast,
DO-1 fails to co-immunoprecipitate Rpb1 from a WCE prepared
from yeast expressing p53
coreD (Figure 2C, lane 4), indistinguish-
able from the negative controls (lanes 1, 3; cells are Myc
2).
Likewise, a polyclonal anti-Pol II (Rpb1) antibody fails to co-IP
Figure 2. The Core Domain of p53 Mediates the p53-Pol II Interaction in Whole Cell Extracts. (A) Domain structures of p53
+ and p53
coreD.
TA1 and TA2, transactivation domains 1 and 2; Tetra., tetramerization domain; Reg., regulatory domain. (B) p53 immunoblot analysis of cells
expressing p53
+ (strain SY1000) and p53
coreD (strain SY1004) regulated by the GAL1 promoter. Cells were grown in rich medium containing 1.8%
raffinose and 0.2% galactose. p53 was detected through use of the DO-1 mAb; expression levels were internally normalized to those of Pgk1. (C) The
Pol II large subunit co-immunoprecipitates with p53
+, but not with p53
coreD, in yeast WCEs. Immunoprecipitates were obtained from WCEs isolated
from strains SY1000 and SY1004 cultivated as above using Myc- or p53-specific antibodies (9E10 or DO-1, respectively) (lanes 1–4). Rpb1 was detected
using anti-CTD antiserum. Lanes 1 and 3 serve as negative controls as cells do not express a Myc-tagged protein. (D) p53
+, but not p53
coreD, co-IPs
with Pol II. Immunoprecipitates were generated using either pre-immune or anti-Pol II (CTD) antiserum (lane 1–4) from extracts as above. p53 and
p53
coreD were detected using DO-1.
doi:10.1371/journal.pone.0022183.g002
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coreD in the reciprocal reaction, even though it efficiently co-IPs
p53
+ (Figure 2D, compare lane 4 vs. 2). These results indicate that
the core domain is necessary for the p53-Pol II interaction in
whole cell extracts.
Core domain point mutations suppress p53-mediated
synthetic growth defects
p53-expressing cells exhibit elevated sensitivity to the anti-
elongation drug, 6-azauracil (6-AU), and synthetic growth
phenotypes in combination with mutations in transcription
elongation factors [29]. To test the involvement of the core
domain, we asked whether oncogenic point mutations localized
within this domain would impact these phenotypes. We tested
both contact (R273H) and conformational (V143A, R175H) point
mutations. As illustrated in Figure 3 (panels A and D), expression
of moderate levels of p53
+, comparable to what is seen in activated
human cell lines [29], is mildly toxic (compare growth of p53
+ vs.
p53
2 cells on 0.4% galactose-containing medium). When
combined with an inhibitor of Pol II elongation – either 6-AU
or mycophenolic acid (MPA) [31] – p53
+ causes sickness or
lethality. Strikingly, both V143A and R175H conformational
point mutations suppress these phenotypes (Figure 3, panels A, C
and D; note that p53 expression in panel C is under control of the
constitutive ADH1 promoter). And although less robust, suppres-
sion is also conferred by the R273H point mutation (panels A, D).
These suppressing effects are unlikely to stem from instability of
either mutant protein, since intracellular levels of p53
+, p53
R273H
and p53
V143A are essentially equivalent (panel B; see also panel F).
We next asked whether loss of core domain function alleviates
the severe slow growth phenotype of p53
+ cells depleted of the
elongation factor TFIIS (Dst1) [29]. TFIIS facilitates Pol II
elongation by enhancing the intrinsic 39-end cleavage and
backtracking activity of Pol II following its stalling or arrest. In
this assay (Figure 3E), p53 derivatives were under control of the
ADH1 promoter and cells were spotted on either non-selectable
medium (SDC; serves as a load control) or selectable medium
(SDC -Leu, -His). Strikingly, the slow growth phenotype of p53
+
dst1D cells is entirely alleviated by the R175H point mutation
(compare row 5 with rows 4, 6). Once again, this suppression
cannot be accounted for by instability (or diminished expression) of
the mutated protein (Figure 3F).
Our observations that synthetic growth defects arise when p53
is combined with either an elongation inhibitor or depletion of
TFIIS are consistent with the possibility that p53 negatively
regulates Pol II elongation. Nonetheless, it is conceivable that these
synthetic phenotypes, particularly those obtained through use of
drugs, have little to do with Pol II elongation. To address this
concern, we asked whether a mutation in a gene whose
physiological function is unrelated to Pol II elongation elicits
comparable synthetic growth defects when combined with
expression of p53
+. For this purpose we selected a mutation,
ipk1D, that was previously shown to elicit strong genetic
interactions when combined with 6-AU [32]. As Ipk1 encodes a
nuclear protein required for synthesis of 1,2,3,4,5,6-hexakispho-
sphate, it is unlikely that its deletion directly affects Pol II
elongation. When combined with ipk1D, moderate p53
+ expres-
sion fails to trigger synthetic sickness beyond that observed in the
WT parent BY4741 strain (Figure 3G; compare to Figure 3A),
contrasting significantly with the synthetic sickness of the p53
+
dst1D strain (Figure 3E). Taken together, the genetic interaction
data are consistent with a model in which p53 impedes Pol II
elongation, and that missense oncogenic mutations within the core
domain suppress this activity.
p53 influences Pol II density at constitutively transcribed
genes
We next asked whether p53’s association with polymerase
influenced the density of Pol II within gene coding regions. This
might be anticipated if p53 impacted Pol II processivity (stalling),
elongation rate, or both. As shown in Figure 4, p53 increased Pol
II density within the PMA1 59-UTR, ORF and 39-UTR
(Figure 4A, compare p53-expressing [lanes 2–5] vs. p53-non-
expressing cells [lanes 7–10]; quantified in Figure 4B). Pol II
density is also increased within the ACT1 promoter and ORF
(Figure 4C). Increased Pol II density is most pronounced at the 59-
UTR/promoter of both genes. Interestingly, the p53-dependent
effect is evident in cells that have not been induced by galactose
and express p53 at a constitutively low level (,10% the level
present in induced cells [29]). Increasing intracellular p53 levels
does not cause a further increase in Pol II density at either gene,
although the reason for this is unclear. To test whether increased
Pol II is correlated with the transcription of either PMA1 or ACT1,
we performed northern blot analysis. Transcript levels of these two
genes were not significantly affected by increased Pol II abundance
in p53-expressing cells (Figure 4D). This result implies that
increased Pol II density stems from impaired elongation rate.
Output is not affected since the rate-limiting step for these two
genes, as suggested by the data, is apparently at initiation. These
observations are consistent with the idea that p53’s association
with Pol II diminishes its elongation efficiency.
p53 impairs Pol II processivity at episomal PHO5/lacZ
genes in a core domain-dependent manner
The forgoing observations and previous results [29] raise the
possibility that p53 perturbs transcription elongation. To test this
idea further, we performed an in vivo transcription elongation assay
that was developed for detection and analysis of factors involved in
transcription elongation [33]. This assay is based on comparison of
Pho5 acid phosphatase expression arising from two transcription
units sharing the same promoter, ORF, and terminator but
differing in the length of their 39-untranslated regions (39-UTR)
(illustrated in Figure 5A). Mutations in elongation factors cause a
greater reduction in the steady-state levels of long versus short
transcript (termed the GLAM ratio), and this can be conveniently
monitored by measuring acid phosphatase activity [33].
Plasmids bearing either short or long transcription units (Figure 5A)
weretransformed into isogenicp53
+and p53
2strains, and the GLAM
ratio of p53
+ cells was compared to that of p53
2 cells. In p53
2 cells,
expression of long versus short transcription units was fairly similar
(GLAM ratio ,0.8; Figure 5B). In contrast, p53
+ cells exhibit nearly a
60% reduction in phosphatase activity of long transcript-expressing
cells relative to short transcript-expressing cells. This deficiency in
mRNA biogenesis is comparable to cells lacking TFIIS (dst1D), and is
consistent with the idea that p53 can suppress Pol II processivity. It is
also consistent with observations reported above that the p53-induced
increase in Pol II density at PMA1 and ACT1 is most pronounced
within the 59-end of these genes (Figure 4, panels B and C). We next
investigated if the core domain plays a role in this process by testing
whether the V143A conformational mutation could alleviate this
reduction. As shown in Figure 5B, the V143A missense mutation
restored the GLAM ratio to a level indistinguishable from that seen in
p53
2cells. To rule out the possibility that the V143A effect arose from
diminished p53 levels, we performed immunoblot analysis. This assay
revealed that p53
V143A levels were comparable to those of p53
+
(Figure 5C, upper panel, lanes 4–6 vs. 1–3). Finally, to test whether
p53 elicits a synergistic effect when combined withdst1D,w em e a s u r e d
the GLAM ratio of dst1Dcells expressing p53
+. However, we observed
p53 Binds RNA Polymerase through Its Core Domain
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mutation alone (Figure 5B) despite a high level of p53
+ expression
(Fig. 5C, lower panel). While the reason for this is unclear (see
Discussion), the GLAM data suggest that p53 can impede Pol II
processivity in a modeleukaryoticsystem, and that integrity of the core
domain of p53 is required for this activity.
Discussion
We demonstrate in this study that the p53 tumor suppressor can
physically and functionally interact with the large subunit of RNA
polymerase II. This physical interaction involves the core DNA-
binding domain of p53 and, at minimum, the Ser5-phosphorylat-
Figure 3. Core domain Mutations Abolish Synthetic Growth Phenotypes Observed in p53-Expressing Cells. (A) Fivefold serial dilutions
of yeast cells(BY4741 background) expressing p53
+,p 5 3
R273H or p53
V143A behind the GAL1 promoter or expressing no ectopic protein (p53
2). Cells were
spotted onto syntheticrichmediumcontaining either2%glucose (SDC)or 1.6%raffinose/0.4%galactose; 6-azauracil(6-AU) was addedwhere indicated.
Cells were incubated at 30uC for 3 to 6 days. (B) Immunoblot analysis of p53
+ and p53 core domain mutant-expressing strains grown in liquid synthetic
medium containing 1.6% raffinose/0.4% galactose. p53
+ and its mutant derivatives were detected using the 1801 mAb. (C) As in A, except p53
expression was regulated by the ADH1 promoter and BY4741 cells were grown on synthetic rich medium containing 2% glucose in the absence or
presenceof mycophenolic acid (MPA). (D)Spot dilutionanalysis of p53
+ andp53 mutant-expressing cellsas inA exceptgrownon synthetic rich medium
containing either2%glucose or 1.5%raffinose/0.5% galactose in theabsence or presence of MPA. (E) Fivefoldserialdilutions of strainBY4741 (rows 1–3)
or its isogenic dst1D counterpart (rows 4–6) transformed with p53
+- or p53
R175H-expressing plasmids (or empty vector; p53
2) as in C and spotted onto
synthetic rich medium. The SDC panel, while non-selective, shows that roughly equivalent numbers of cells were spotted. Note that in replicate
experiments, p53
+ BY4741 cells exhibited a slow growth phenotype on SDC -Leu, -His similar to that seen in C. (F) Immunoblot analysis of p53
+ and
p53
R175H expression in the dst1D mutant grown in synthetic rich medium containing 2% glucose. (G) Spot dilution analysis of p53
+ and p53
V143A-
expressing BY4741 ipk1D cells grown on synthetic medium containing either 2% glucose (SDC) or 1.6% raffinose/0.4% galactose as indicated.
doi:10.1371/journal.pone.0022183.g003
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the Ser5-phosphorylated CTD (and to a lesser degree, the Ser2-
phosphorylated CTD) bind recombinant human p53 in an in vitro
pull-down assay. Given that human Rpb1 has 52 heptad repeats,
the intrinsic affinity of p53 for the phosphorylated CTD is likely to
be much higher than we observed with biotinylated peptides
containing four repeats; thus the data reported in Figure 1 may
understate the difference in p53’s affinity for the phosphorylated
vs. unphosphophorylated CTD. Interaction of p53 with the
phosphorylated CTD is consistent with our previous work which
demonstrated that the Ser5 phosphorylated Pol II subunit co-
purifies with p53 from yeast WCEs [29]. Physical interaction of a
gene-specific transcription factor with the Pol II CTD is unusual,
but not unprecedented. It has been shown in at least one other
case, that of the HIV regulatory protein Tat [34]. Tat’s interaction
with the CTD appears to affect CTD phosphorylation by CDK2/
cyclin E.
Several lines of evidence suggest that the core DNA-binding
domain of p53 is required for its physical and function interaction
with Pol II. First, a p53 mutant lacking amino acids 91–294,
termed p53
coreD, fails to co-purify with the Pol II large subunit
from yeast WCEs using either p53- or Rpb1-specific antibodies.
This is in contrast to full-length p53, which co-immunoprecipitates
with Rpb1 using either antibody. Second, oncogenic point
mutations within the core domain, particularly those that disrupt
its tertiary structure (V143A and R175H), suppress the synthetic
Figure 4. p53 Increases Pol II Density at Constitutively Transcribed Genes. (A) Pol II ChIP analysis of the PMA1 gene in p53
+ and p53
2 cells.
Depicted is a multiplex PCR analysis (resolved on an 8% polyacrylamide gel) of DNA purified from immunoprecipitated chromatin samples isolated
from SY1000 (PGAL1- p53) and SLY101 (p53
2) cells subjected to a 2% galactose induction for 0, 60, 120 and 180 min. Immunoprecipitations were
conducted using pre-immune (lanes 1, 6) or anti-CTD antiserum (lane 2–5, 7–10). Lane 11, DNA isolated from chromatin used in the ChIPs of lanes 1
and 2. An ORF-free region on chromosome V (ARS504) was co-amplified with the PMA1 loci, and serves as a non-specific IP control. (B) Summary of Pol
II ChIP assays of the PMA1 59-UTR, ORF, and 39-UTR in p53
+ and p53
2 cells conducted as in panel A. Depicted is Pol II abundance at each locus (net
signal, immune minus pre-immune) relative to ARS504 (net signal, immune minus pre-immune). Shown are means 6 S.D; N=2. (C) As in panel B,
except Pol II ChIP analysis of the ACT1 gene. (D) Northern analysis of PMA1 and ACT1 in p53
+ and p53
2 cells following addition of galactose for the
indicated times. Transcript levels were normalized to those of SCR1 and are presented in arbitrary units (shown are means 6S.D; N=2).
doi:10.1371/journal.pone.0022183.g004
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factors TFIIS or Isw1 (Figure 3 and data not shown), or of yeast
cultivated in the presence of the anti-elongation drugs 6-AU or
MPA. Third, the V143A conformational mutation suppresses p53-
mediated reduction of Pho5 phosphatase encoded by a long
transcript, suggesting that the core domain is important for the
reduction in Pol II processivity seen in p53
+ cells.
Notably, p53 regulates transcription in yeast cells independent
of its DNA-binding activity. This follows from our previous work
[29] as well as from the fact that none of the genes evaluated here
– PMA1, ACT1 and PHO5/lacZ – bear consensus p53-response
elements, either within their promoters or coding regions. Given
this, we propose the following model. p53, through its core
domain, physically interacts with the Ser5-phosphorylated CTD of
elongating Pol II. By a mechanism that is as yet unclear, p53
negatively affects Pol II processivity. One way that it could do this
is by displacing elongation factors bound to the transcription
elongation complex (TEC). An appealing candidate is TFIIS,
which binds Pol II cooperatively with the elongation factor Paf1C
[28], and whose depletion strongly impairs Pol II processivity at
the episomal PHO5::lacZ gene (this study and [33]). Consistent
with this idea, p53 elicits as strong an effect on Pol II elongation at
PHO5::lacZ as does depletion of TFIIS. Moreover, the combina-
tion of p53 and dst1D elicits no more severe effect on Pol II
processivity than either perturbation alone. Clearly, this cannot be
a general mechanism by which p53 acts in this model system,
given the strong synthetic growth phenotype of a p53
+ dst1D strain.
For at least one essential gene, p53 must be acting in a different
pathway than TFIIS, hence the synergy seen when the two insults
are combined.
A major consideration of this work is whether the novel activity
of p53 identified in yeast is conserved in higher eukaryotes. In fact,
several studies have shown a direct interaction between p53 and
human elongation factors such as TFIIH, ELL and hPAF1C
[25,27,28]. This raises the possibility that p53’s negative effect on
transcription elongation is conserved from yeast to humans. It is
likely that p53’s interaction with the TEC will be highly regulated
in mammalian cells. As guardian of the genome, p53 might exhibit
this activity to suppress expression of pro-proliferative genes in
response to genotoxic stress. Mammalian cells contain much
larger, intron-rich genes. Thus, the rather subtle elongation defects
elicited by p53 on the representative yeast genes studied here,
particularly with respect to transcriptional output, may signifi-
cantly underestimate its impact on the much longer genes of
higher eukaryotes. Complementing our results, Hatakeyama’s lab
has shown that p53 can inhibit transcription elongation by
Figure 5. p53
+, but not the Oncogenic Mutant p53
V143A , Impairs Pol II Processivity on the Episomal PHO5-lacZ Gene. (A) Physical maps
of PHO5 reporter genes under GAL1 regulation used in the processivity assay. (B) Isogenic DST1
+ and dst1D strains (SLY101 background) expressing
the indicated p53 derivatives were transformed with either PGAL-PHO5 or PGAL-PHO5::lacZ reporter plasmids, and grown in synthetic selectable
medium containing 1% raffinose and 1% galactose to early log phase. Cells were harvested and PHO5 expression levels were inferred by an acid
phosphatase assay. GLAM ratio refers to the acid phosphatase activity of cells expressing the long transcript (PHO5-lacZ) relative to those expressing
the short transcript (PHO5). Depicted are mean values 6 S.E.M. of six independent transformants of each indicated strain/plasmid combination. Single
asterisk signifies a significant difference between the indicated values (P,0.01; two-tailed t test); double asterisk signifies P,0.0005. (C) Western blot
analysis of p53
+ and p53
V143A levels in DST1
+ and dst1D strains employed in the GLAM assay (panel B). p53 derivatives were detected using the 1801
mAb; their relative levels, normalized to those of Pgk1, are provided below each lane. S, short transcript expressing cells; L, long transcript plasmid
transformed cells; E, cells transformed with empty vector; T.U., transcription unit.
doi:10.1371/journal.pone.0022183.g005
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transcription by suppressing transient pausing [27]. Interestingly,
through use of ChIP, we have observed a low level of p53
association with the coding regions of several oncogenes in human
RKO and MCF7 cell lines in response to genotoxic stress (D.
Gross, R. Beckerman, A. Barsotti and C. Prives, unpublished
observations). While the biological significance of this observation
is unclear, it is consistent with the premise that p53 can negatively
affect the expression of pro-proliferative genes through a
mechanism that involves its physical association with the Pol II
transcription elongation complex.
Materials and Methods
Strain Construction
Strains used in this study are listed in Table 1. To construct a strain
expressing p53 deleted of its core domain (amino acids 91–294)
(p53
CoreD) from an integrated expression cassette, we used a
modification of the cloning-free PCR-based allele replacement
strategy of Rothstein and colleagues [35] essentially as described
previously [29]. Strain YYO2 was used as recipient and genomic
DNA isolated from SY1000, harboring an integrated PGAL1-p53 gene
at the LEU2 l o c u s ,w a su s e da st e m p l a t e .LEU2 -PGAL1-p53(codons 1–
90) was fused to p53(codons 295–393) - LEU2 through use of a 24 nt
adaptamer homologous to codons 295–302. The resultant fusion was
targeted to the leu2-3,112 locus of YYO2 by homologous
recombination, and the PGAL1-p53
CoreD integrant confirmed by
genomic PCR analysis and DNA sequencing. For all PCR reactions,
amplifications were performed using Phusion High Fidelity DNA
Polymerase(New England Biolabs). GAL1-regulated centromeric p53
expression vectors (Yp53, p53
R273H and p53
V143H) were generously
providedbyBertVogelstein.ADH1-regulatedcentromericexpression
vectors pRB16 and p53
R273H were generously provided by Rainer
Brachmann and Carol Prives, respectively.
Genetic Assays
For spot dilution assays, BY4741 was transformed with plasmids
encoding wild-type (WT) p53, p53 core domain mutants, or vector
Table 1. Yeast Strains.
Strain Genotype Source or reference
SLY101 MATa ade
2 can1-100 cyh2
r his3-11,15 leu2-3,112 trp1-1 ura3 [40]
YYO2 SLY101; p53-hsp82 [29]
SY1000 YYO2; leu2-3::PGAL1-p53-LEU2 [29]
SY1004 YYO2; leu2-3::PGAL1-p53
CoreD -LEU2 This study
BY4741 MATa his3D1 leu2D0 met15D0 ura3D0 Research Genetics
YDR007W BY4741; trp1D Research Genetics
K1000 YDR007W; pRS316 (URA3 CEN6), pRS314 (TRP1- CEN6) This study
K1001 YDR007W; Yp53 (PGAL1-p53 URA3 -CEN6), pRS314 This study
K1002 YDR007W; p53
R273H (PGAL1-p53
R273H TRP1-CEN6), pRS316 This study
K1003 YDR007W; p53
V143A (PGAL1-p53
V143A TRP1-CEN6), pRS316 This study
K1004 BY4741; pRS313 (HIS3 -CEN6), pRS315 (LEU2- CEN6) This study
K1005 BY4741; pRB16 (PADH1-p53 HIS3 -CEN6), pRS315 This study
K1006 BY4741; p53
R175H (PADH1-p53
R175H LEU2-CEN6), pRS313 This study
YGL043W BY4741; dst1D, pRS313, pRS315 Research Genetics
YGL043W1 YGL043W; pRB16, pRS315 This study
YGL043W2 YGL043W; p53
R175H, pRS313 This study
YDR315C BY4741; ipk1D Research Genetics
YDR315C1 BY4741; ipk1D, pRS316 This study
YDR315C2 BY4741; ipk1D, Yp53 This study
YDR315C3 BY4741; ipk1D, p53-1
V143A (PGAL1-p53
V143A URA3-CEN6) This study
G1000 SLY101; pSCh202 (PGAL1-PHO5 URA3 CEN6), pRS314 This study
G1001 SLY101; pSCh212 (PGAL1-PHO5 URA3 CEN6), pRS314 This study
G1002 SLY101; pSCh202, Yp53 This study
G1003 SLY101; pSCh212, Yp53 This study
G1004 SLY101; pSCh202, Yp53
V143A This study
DCY103 SLY101; dst1D [29]
D1000 DCY103; pSCh202, pRS314 This study
D1001 DCY103; pSCh212 , pRS314 This study
D1002 DCY103; pSCh202, Yp53 This study
D1003 DCY103; pSCh212, Yp53 This study
D1004 DCY103; pSCh202, Yp53
V143A This study
D1005 DCY103; pSCh212, Yp53
V143A This study
doi:10.1371/journal.pone.0022183.t001
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selectable medium. Cultures were then diluted to OD600 0.5 and
transferred to a 96-well microtiter dish. Each was then fivefold
serial diluted using double distilled water and applied to solid
synthetic medium containing 2% glucose, 1.6% raffinose/0.4%
galactose, or 1.5% raffinose/0.5% galactose with or without
elongation inhibitory drugs (6-AU or MPA). Cells were grown at
30uC for 3,6 days to allow formation of visible colonies.
Western Blot Analysis
Isolation of WCEs was conducted essentially as described [36].
WCEs were separated on 10% SDS-polyacrylamide gels and
electroblotted onto nitrocellulose membranes (Bio-Rad). Blotted
membranes were incubated with antibodies specific for p53 (DO-1
[Santa Cruz Biotechnology, Inc.] or 1801 [hybridoma superna-
tants generated at Cold Spring Harbor Laboratory; gift of Carol
Prives]) or Pgk1 (Molecular Probes) and then incubated with
horseradish peroxidase-conjugated anti-mouse or anti-rabbit
secondary antibodies. Protein bands were visualized by using
ECL Plus Western blotting detection reagents (GE Healthcare)
and detected and quantified on a Storm 860 PhosphorImager
utilizing Image Quant TL v.2003.02 software.
Co-Immunoprecipitation Assay
Co-immunoprecipitation was performed as described previously
[29], with yeast strains SY1000 and SY1004 grown to early log
phase in rich media containing 1.8% raffinose and 0.2% galactose.
The following antibodies and amounts were used for each IP: [i]
p53 (DO-1; Santa Cruz), 2 mg; [ii] Myc (9E10; Santa Cruz), 2 mg;
and [iii] Pol II CTD (rabbit antiserum raised against a GST-
mouse CTD fusion protein bearing 52 heptad repeats [37]), 3 ml.
GLAM Assay
SLY101 and its dst1D counterpart were transformed with
plasmids expressing p53
+ or p53
V143A, or with vector alone
(pRS316). These transformants were then transformed with either
short transcript plasmid (pSCh202, containing PGAL-PHO5) or long
transcript plasmid (pSCh212, containing PGAL-PHO5::lacZ) (kindly
provided by Daniel Ginsburg and Sebastian Chavez), and grown
to OD600 0.3–0.7 in synthetic medium lacking both tryptophan
and uracil and containing 1% galactose and 1% raffinose. Cells
were collected by centrifugation and acid phosphatase activity was
assayed as described [33].
CTD Pull-Down Assay
A modified CTD pull-down assay [38] was performed. Briefly,
0.5 mg of biotinylated peptides (comprised of four CTD heptad
repeats; Anaspec) were bound to 50 ml of streptavidin-coated
dynabeads (Invitrogen) by incubation in the presence of 100 mlo f
high salt binding buffer (25 mM Tris-HCl [pH 8.0]); 1 M NaCl;
1 mM dithiothreitol; 5% glycerol; 0.03% Nonidet P-40) at 4uC for
2 hr. The peptide-bound beads were washed once with 500 mlo f
CTD-wash buffer (25 mM Tris-HCl [pH 8.0]; 50 mM NaCl;
1 mM dithiotheritol; 5% glycerol; 0.5 mg/ml BSA; 0.1% Triton X-
100), then pre-incubated for 2 hr with 500 ml of CTD-binding
buffer (same as CTD-wash buffer except contained 1 mg/ml BSA)
to block non-specific binding. Peptide-bound beads were then
resuspended in 100 ml of CTD binding buffer and approximately
120 ng of E.coli expressed HA-p53 (generous gift of O. Laptenko
and C. Prives, Columbia University) were incubated at 4uC for
2 hr. The beads were collected magnetically and the supernatant
saved as the unbound fraction. Beads were washed with CTD-
wash buffer 3 times and 1/5 volume of each bound fraction and
each unbound fraction was resuspended in 66sample buffer and
subjected to SDS-PAGE. Western blot analysis was performed
using monoclonal antibody 1801.
Chromatin Immunoprecipitation (ChIP)
ChIP was conducted essentially as described [29]. Briefly,
400 ml of soluble, crosslinked chromatin were immunoprecipitated
using 3 ml CTD antiserum (described above); as the negative
control, an equivalent volume of chromatin was immunoprecip-
itated using 3 ml pre-immune serum. DNA, purified from the IP,
was dissolved in 25–30 ml distilled water; 2 ml were used as
template in a multiplex PCR performed in the presence of a-
32P-
dATP. Amplified DNA was electrophoretically resolved on an 8%
polyacrylamide gel using PhosphorImager. For quantification, we
subtracted a representative pre-immune ChIP sample from each
IP signal prior to calculating Qlocus (=IP locus/Inputlocus). PCR
primers used were as follows (all coordinates relative to ATG):
ACT1 promoter (forward, 2294 to 2272; reverse, 245 to 268);
ACT1 ORF (forward, +606 to +629; reverse, +1000 to +978);
PMA1 promoter (forward, 2370 to 2349; reverse, 251 to 272),
PMA1 coding region (forward, +1010 to +1032; reverse, +1235 to
+1215); PMA1 39-UTR (forward, +2018 to +2040; reverse, +2177
to +2154).
Northern Analysis
RNA isolation, formaldehyde gel electrophoresis and blotting to
nylon membranes were conducted as described previously [29].
Hybridization probes spanned the following coordinates (relative
to ATG for ACT1 and PMA1): ACT1, +606 to +1000; PMA1,
+2742 to +2872; SCR1, +343 to +467.
p53 Binding Site Search
To search for potential p53 binding sites within the coding and/
or flanking regions of ACT1, PMA1, PHO5 and lacZ, the ‘‘find
sequence function’’ in Vector NTI (ver. 11.0) was used with
‘RRRCWWGYYY’ as the search string, where ‘R’=purine,
‘Y’=pyrimidine, and ‘W’=A or T. The search was first
conducted with the tolerance set to 0 mismatches with follow-up
searches of up to 3 mismatches to detect any potential p53 binding
sites, defined as a 20 bp sequence consisting of two repeats of
RRRCWWWGYYY separated by 0–13 bp [39]. None were
identified.
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